Structure-based drug design, a terminology used to describe rational drug design by complementing the structure, spatially and chemically, of the target macromolecule, is rapidly developing as one of the innovative approaches to drug discovery. A growing volume of protein structure data and new techniques of protein structure determination make this all possible. The method of structure-based drug design and a specific example of the design of influenza virus neuraminidase is briefly presented. A whole new class of influenza virus neuraminidase inhibitors has been designed that can potentially be developed as antiinfluenza drugs.
No takes yet. Share an insight, caveat, or question.
Luo et al. (1997) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: